Hasbani Follows Up The Death Of Farah Kassab And Issues Two Decisions And Two Letters To The General

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:

In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,

Health Minister Ghassan Hasbani took the following actions:

The issuance of a decision on the prevention of surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
The issuance of a decision on the prevention of surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.

These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:

Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
J06BA02	IMMUNOREL	BioHuman	Human normal immunoglobulin - 5g/100ml	5%	Injectable solution	L.L
J06BB01	IMMUNORHO	BioHuman	Human anti-D (rh) immunoglobulin - 300mcg	300mcg	Injectable dry powder+diluent	5,794,649 L.L
J06BB04	IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B LFB	BioHuman	Hepatitis B immunoglobulin (human) - 100UI/ml	100UI/ml	Injectable solution	6,853,730 L.L
J06BB04	IMMUNOGLOBULINE HUMAINE DE L'HEPATITE B LFB	BioHuman	Hepatitis B immunoglobulin (human) - 500UI/5ml	500UI/5ml	Injectable solution	26,599,935 L.L
J07BB01	INFLUVAC TETRA	B	Influenza virus surface antigens inactivated (haemagglutinin and neuraminidase) - 15mcg/4strains/0.5ml		Injectable suspension	970,254 L.L
J07BB02	INFLUVAC	B	Grippal virus surface antigen 3strains - 15mcgx3strains/0.5ml		Injectable suspension	573,821 L.L
J07CA06	INFANRIX IPV + HIB	B	Poliomyelitis virus type 3 inactivated(Prefilled syringe) - 32D.U., Poliomyelitis virus type 2 inactivated(Prefilled syringe) - 8D.U., Poliomyelitis virus type 1 inactivated(Prefilled syringe) - 40D.U., Bordetella pertussis antigen(Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg, Tetanus toxoid (Prefilled syringe) - ≥40IU, Diphtheria toxoid (Prefilled syringe) - ≥30IU, H. Influenza type b polysaccharide(Vial) - 10mcg		Injectable dry powder+suspension	3,014,239 L.L
J07CA09	INFANRIX HEXA	B	Diphteria toxoid purified (Prefilled syringe) - ≥30IU/0.5ml, Tetanus toxoid purified (prefilled syringe) - ≥40IU/0.5ml, Bordetella pertussis antigen (Prefilled syringe) - toxoid 25mcg+filamentous haemaglutinin 25mcg+pertactin 8mcg/0.5ml, Poliomyelitis virus type 1 antigen (prefilled syringe) - 40D.U./0.5ml, Poliomyelitis virus type 2 antigen(prefilled syringe) - 8D.U./0.5ml, Poliomyelitis virus type 3 antigen (prefilled syringe) - 32D.U./0.5ml, HBs Antigen (prefilled syringe) - 10mcg/0.5ml, H. Influenza type b polysaccharide (Vial) - 10mcg/0.5ml		Injectable suspension	4,230,416 L.L
L01CE02	IRINOGEN	G	Irinotecan HCl - 100mg	100mg	Injectable solution	5,239,642 L.L
L01CE02	IRINOGEN	G	Irinotecan HCl - 100mg	100mg	Injectable solution	5,239,642 L.L
L01CE02	IRINOTECAN GP PHARM	G	Irinotecan HCl trihydrate - 100mg/5ml	100mg/5ml	Injectable concentrated solution	5,239,642 L.L
L01CE02	IRINOTECAN HYDROCHLORIDE	G	Irinotecan HCl - 100mg/5ml	100mg/5ml	Injectable concentrate for solution	2,085,644 L.L
L01CE02	IRINOTECAN THYMOORGAN	G	Irinotecan HCl - 100mg/5ml	100mg/5ml	Injectable concentrated solution	6,111,796 L.L
L01CE02	IRNOCAM 100	G	Irinotecan HCl - 100mg/5ml	100mg/5ml	Injectable solution	7,320,947 L.L
L01CE02	IRINOTECAN THYMOORGAN	G	Irinotecan HCl - 40mg/2ml	40mg/2ml	Injectable concentrated solution	2,123,271 L.L
L01CE02	IRNOCAM 40	G	Irinotecan HCl - 40mg/2ml	40mg/2ml	Injectable solution	908,694 L.L
L01EA01	IMAREM	G	Imatinib (mesylate) - 400mg	400mg	Tablet, film coated	64,682,117 L.L
L01EA01	IMATINIB GP PHARM	G	Imatinib - 400mg	400mg	Tablet, coated	26,083,945 L.L
L01EA01	IMATINIB NEAPOLIS	G	Imatinib - 400mg	400mg	Tablet, film coated	36,046,335 L.L
L01EA01	IMATINIB SHILPA MESYLATE	G	Imatinib - 400mg	400mg	Tablet, film coated	21,518,059 L.L
L01EA01	IMATINIB SPC	G	Imatinib - 400mg	400mg	Tablet, film coated	62,161,280 L.L
L01EA01	IMATINIB GP PHARM	G	Imatinib - 100mg	100mg	Tablet, coated	26,083,945 L.L
L01EA01	IMATINIB NEAPOLIS	G	Imatinib - 100mg	100mg	Tablet, film coated	31,085,276 L.L
L01EA01	IMATINIB NEAPOLIS	G	Imatinib - 100mg	100mg	Tablet, film coated	16,144,207 L.L
L01EA01	IMATINIB SHILPA MESYLATE	G	Imatinib - 100mg	100mg	Tablet, film coated	14,396,132 L.L
L01EA01	IMATINIB SPC	G	Imatinib - 100mg	100mg	Tablet, film coated	29,473,181 L.L
L01EA05	ICLUSIG	B	Ponatinib - 15mg	15mg	Tablet, film coated	103,555,839 L.L
L01EA05	ICLUSIG	B	Ponatinib - 45mg	45mg	Tablet, film coated	207,092,651 L.L
L01EB01	IRESSA	B	Gefitinib - 250mg	250mg	Tablet, fim coated	135,027,509 L.L
L01EF01	IBRANCE	B	Palbociclib - 75mg	75mg	Capsule	172,164,216 L.L